^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MAD2L2 overexpression

    i
    Other names: MAD2L2, Mitotic Arrest Deficient 2 Like 2, MAD2B, REV7, MAD2 (Mitotic Arrest Deficient, Yeast, Homolog)-Like 2, Polymerase (DNA-Directed), Zeta 2, Accessory Subunit, Mitotic Spindle Assembly Checkpoint Protein MAD2B, Mitotic Arrest Deficient 2-Like Protein 2, Mitotic Arrest Deficient Homolog-Like 2, MAD2-Like Protein 2, REV7 Homolog, FANCV, POLZ2, HREV7, MAD2 Mitotic Arrest Deficient-Like 2
    Entrez ID:
    10459
    Related biomarkers:
    Expression
    almost2years
    AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2. (PubMed, J Transl Med)
    AURKB activates MAD2L2 expression to downregulate the p53 DDR pathway, thereby promoting BC progression. Thus, AURKB may serve as a potential molecular marker and a novel anticancer therapeutic target for BC.
    Journal
    |
    AURKB (Aurora Kinase B) • MAD2L2 (Mitotic Arrest Deficient 2 Like 2)
    |
    TP53 expression • MAD2L2 overexpression